mobic and tenidap

A need remains for the development of more effective therapies for the treatment of rheumatoid arthritis (both NSAIDs and DMARDs). The NSAIDs remain the cornerstone of symptomatic therapy, but concern remains about their safety, potential for the delay in commencing definitive therapy and theoretical pro-inflammatory effects. Each of the NSAIDs reviewed here do provide an advantage over therapies previously available and should prove to be useful additions to the rheumatologists' therapeutic armament.

Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Cyclooxygenase Inhibitors; Cytokines; Digestive System; Drug Therapy, Combination; Humans; Indoles; Isoenzymes; Meloxicam; Misoprostol; Nabumetone; Oxindoles; Thiazines; Thiazoles